Setting the standard in early-stage life sciences.

Dr.Pachuda led the life science investment activities of the prior fund (Mountain State Capital SBIC, LP), and has served in leadership roles at MedTech startups as well as at one of the world’s largest MedTech companies (Johnson & Johnson Depuy Synthes). He is a globally-recognized leader in the MedTech industry who combines his clinical, technical, and business experience to identify transformational innovation opportunities and accelerate their path to success. In addition to investment activities, for the past several years, Nick has served as the Chief Operating Officer at Peptilogics, a Mountain State Capital portfolio company where he helped define the company’s strategy and led the successful raising of a $60 million round. Previously, Dr. Pachuda led Global External Innovation for Johnson & Johnson’s orthopedic device division. He created multiple new development, investment, and commercial ventures while at J&J and Arthrex (Digital Surgery & Robotics, Ambulatory Surgery Centers, Sports Medicine, Extremities). He also developed and restructured multiple startups for successful exits, including SBI to Stryker, and Scient’X to Alphatec. Prior to entering the MedTech industry in 2003, Dr. Pachuda practiced as a foot & ankle surgeon in the U.S. for ten years and completed an Orthopedic Trauma Fellowship in Germany.

Kevin previously served as Chief Executive Officer at Biorez, a regenerative medicine startup that was acquired by ConMed in 2022 for $250 million. Prior to joining Biorez, Mr. Rocco studied tissue engineering at Yale University, where he coauthored 17 publications in the field and was a part of the research team with the first US clinical study of a bioresorbable vascular graft in humans. Mr. Rocco began his career as an engineer in new technology development at Covidien (acquired by Medtronic) where he investigated a novel bioresorbable hernia mesh device. Mr. Rocco holds a B.S. and M.S. in Biomedical Engineering from The University of Connecticut and Yale University, respectively. Mr. Rocco lives in New Haven, Connecticut.

Mike is an experienced early-stage investor, successful technology executive, and community leader, and has served as an adviser, investor and board member for dozens of privately held technology companies. In 2018, Mr. Green and Mr. Harbaugh founded Mountain State Capital, a venture capital fund that has invested in a wide variety of technologies and industry sectors ranging from software to life sciences. Prior to becoming a VC, Mr. Green assembled a personal portfolio of angel investments and served on the Board of Directors of Innovation Works, an early-stage seed fund. 10Mr. Green is a successful technology executive, having served as the Senior VP and General Manager of Worldwide Sales for FORE Systems, Inc. where he led sales and grew the company from startup to $800M in annual revenue prior to being acquired by Marconi in 1999 for $4.5 Billion. After FORE Systems, Mr. Green joined Loudcloud, Inc. (founded by Marc Andreesen and Ben Horowitz) and served as President of Field Operations. Loudcloud, one of the world’s first cloud services companies, subsequently became Opsware and was acquired by Hewlett Packard for $1.6 Billion. Mr. Green earned a bachelor's degree in mathematics from Boston University and a master's degree in numerical science from Johns Hopkins University. Mr. Green lives in Morgantown, West Virginia.

Matt has invested in, managed and advised more than 100 technology and life sciences startups over the past twenty years. Mr. Harbaugh currently works with Dr. Pachuda and Mr. Green to manage the investment activities of Mountain State Capital SBIC, LP. Previously, Mr. Harbaugh served as the CEO and COO of Mobile Technologies, LLC, an A.I./M.L. spinout from Carnegie Mellon University, which was acquired by Facebook in August 2013. In addition, Mr. Harbaugh’s prior investment experience includes nearly a decade at Innovation Works, Inc., where he served as Chief Investment Officer from 2006 to 2010 and as Director of External Finance from 2001 to 2006. During his tenure as Chief Investment Officer, Mr. Harbaugh led seed-and early-stage investments in over 50 companies across the life sciences, IT and energy sectors. Mr. Harbaugh received his undergraduate degree from Duke University and received his JD and MBA degrees from the George Washington University. Mr. Harbaugh lives in Pittsburgh, Pennsylvania.

Kenny is a Venture Partner at Neovate Capital Partners, bringing decades of global biopharma experience in drug discovery, early clinical development, and innovative dealmaking. He has held positions of increasing responsibility in early-stage research and development and most recently led a global external innovation team at Johnson & Johnson, focusing on transactions for infectious diseases & vaccines, including relevant RNA platform technologies. During his career at Johnson & Johnson, Dr. Simmen led Infectious Diseases & Vaccines activities across J&J Innovation Centers globally. He coordinated the search, evaluation, and diligence of external assets and technologies, leading to dozens of deals including collaborations, licenses, acquisitions, and equity investments. Dr. Simmen's experience includes diligence and acquisition of companies worth >$4BN, as well as numerous collaboration and licensing agreements and company mentoring through his role in JLABs and the BlueKnight initiative with BARDA. He played a key role as co-inventor and co-developer of the approved Hepatitis C blockbuster antiviral, Simeprevir (OLYSIO), earning him the prestigious Johnson Medal in 2015. He also served as Vice President, interim R&D Leader for Hepatitis, coordinating R&D and external interactions on HBV. Before his innovation roles, he built and led an antiviral drug discovery group and initiated J&J's work on Hepatitis C. Dr. Simmen gained a Ph.D. from the European Molecular Biology Laboratory (EMBL) and a B.Sc. in Molecular Biology from the University of Edinburgh. Kenny currently serves as Advisor, CBO, Board Director, or Scientific Advisory Board Member for biotechs around the globe and is a member of the X Prize Healthspan Judging Panel. Dr. Simmen lives in Oxfordshire, England.

BRITT KOTH brings operational depth through her experience at Johnson & Johnson MedTech and 5 years previous experience in Sales. Mrs. Koth led full product lifecycles from strategic development through global commercialization across multiple therapeutic areas, with expertise spanning both hardware and software solutions. Her background encompasses sales, marketing, and product management, providing deep insights into market dynamics and customer needs. Mrs. Koth's unique combination of field sales experience and healthcare provider relationships delivers invaluable market perspective. Mrs. Koth earned a bachelor's degree in English and Spanish Literature from University of Colorado, and a master's degree in business from Indiana University’s Kelley School of Business. Mrs. Koth lives in Denver, Colorado.

MATT HARBAUGH has invested in, managed and advised more than 100 technology and life sciences startups over the past twenty years. Mr. Harbaugh currently works with Dr. Pachuda and Mr. Green to manage the investment activities of Mountain State Capital SBIC, LP. Previously, Mr. Harbaugh served as the CEO and COO of Mobile Technologies, LLC, an A.I./M.L. spinout from Carnegie Mellon University, which was acquired by Facebook in August 2013. In addition, Mr. Harbaugh’s prior investment experience includes nearly a decade at Innovation Works, Inc., where he served as Chief Investment Officer from 2006 to 2010 and as Director of External Finance from 2001 to 2006. During his tenure as Chief Investment Officer, Mr. Harbaugh led seed-and early-stage investments in over 50 companies across the life sciences, IT and energy sectors. Mr. Harbaugh received his undergraduate degree from Duke University and received his JD and MBA degrees from the George Washington University. Mr. Harbaugh lives in Pittsburgh, Pennsylvania.